1h Free Analyst Time
Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosine-protein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin-1 (NRG1) and is activated by it. It also activated by CSPG5.
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 3, 1, 6 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Report covers products from therapy areas Oncology which include indications Gastric Cancer, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Lung Cancer, Solid Tumor, Esophageal Squamous Cell Carcinoma (ESCC), Gallbladder Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Colorectal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary), Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Hypopharyngeal Cancer, Laryngeal Cancer, Lung Adenocarcinoma, Metastatic Biliary Tract Cancer, Metastatic Hepatocellular Carcinoma (HCC), Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Paranasal Sinus And Nasal Cavity Cancer, Sarcomas, Thyroid Cancer and Triple-Negative Breast Cancer (TNBC).
The latest report Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2019, outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
- The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Overview
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
AVEO Oncology Inc
Celldex Therapeutics Inc
Etubics Corp
Hanmi Pharmaceuticals Co Ltd
Hummingbird Bioscience Pte Ltd
Imugene Ltd
MediaPharma SRL
Merus NV
Novartis AG
Takis Srl
XuanZhu Pharma Co Ltd
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Drug Profiles
AV-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibodies to Inhibit EGFR and ERBB3 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDX-3379 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elgemtumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FCN-411 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMBD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-5209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCLA-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPEV-201959 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Inhibit EGFR, ERBB2 and ERBB3 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
poziotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EGFR, HER2 and HER3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TK-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target HER1, HER2, HER3 and IGF1R for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target HER3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target HER3 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varlitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-5491 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Dormant Products
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Discontinued Products
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Appendix
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by AVEO Oncology Inc, H2 2019
Pipeline by Celldex Therapeutics Inc, H2 2019
Pipeline by Etubics Corp, H2 2019
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2019
Pipeline by Hummingbird Bioscience Pte Ltd, H2 2019
Pipeline by Imugene Ltd, H2 2019
Pipeline by MediaPharma SRL, H2 2019
Pipeline by Merus NV, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Takis Srl, H2 2019
Pipeline by XuanZhu Pharma Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019 (Contd..2), H2 2019
List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aslan Pharmaceuticals Ltd
- AstraZeneca Plc
- AVEO Oncology Inc
- Celldex Therapeutics Inc
- Etubics Corp
- Hanmi Pharmaceuticals Co Ltd
- Hummingbird Bioscience Pte Ltd
- Imugene Ltd
- MediaPharma SRL
- Merus NV
- Novartis AG
- Takis Srl
- XuanZhu Pharma Co Ltd
